{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T04:46:26Z","timestamp":1773809186772,"version":"3.50.1"},"reference-count":27,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Army Medical University STIEP","award":["2025XQN20"],"award-info":[{"award-number":["2025XQN20"]}]},{"DOI":"10.13039\/501100014869","name":"Clinical Research Special Project at the Second Affiliated Hospital of Army Medical University","doi-asserted-by":"publisher","award":["2024F026"],"award-info":[{"award-number":["2024F026"]}],"id":[{"id":"10.13039\/501100014869","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012457","name":"Chongqing Science and health joint project","doi-asserted-by":"publisher","award":["2021MSXM299"],"award-info":[{"award-number":["2021MSXM299"]}],"id":[{"id":"10.13039\/501100012457","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019030","name":"Chongqing Technology Innovation and Application Development Project","doi-asserted-by":"publisher","award":["CSTB2023TIAD-STX0008"],"award-info":[{"award-number":["CSTB2023TIAD-STX0008"]}],"id":[{"id":"10.13039\/501100019030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018684","name":"National Health Commission","doi-asserted-by":"publisher","award":["WKZX2023CX080001"],"award-info":[{"award-number":["WKZX2023CX080001"]}],"id":[{"id":"10.13039\/501100018684","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Hematology"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/16078454.2026.2642515","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T03:50:42Z","timestamp":1773805842000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of TPO-RA combined with sirolimus in the treatment of relapsed immune thrombocytopenia"],"prefix":"10.1080","volume":"31","author":[{"given":"Dan","family":"Wang","sequence":"first","affiliation":[{"name":"The Xinqiao Hospital of Army Medical University","place":["Chongqing, People\u2019s Republic of China"]},{"name":"The General Hospital of Western Theater Command","place":["Chengdu, People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[{"name":"The Xinqiao Hospital of Army Medical University","place":["Chongqing, People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aoxue","family":"Tan","sequence":"additional","affiliation":[{"name":"The Xinqiao Hospital of Army Medical University","place":["Chongqing, People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3323-4563","authenticated-orcid":false,"given":"Jinqiong","family":"Li","sequence":"additional","affiliation":[{"name":"The Xinqiao Hospital of Army Medical University","place":["Chongqing, People\u2019s Republic of China"]},{"name":"Lijiang People's Hospital","place":["Yunnan, People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoli","family":"Chen","sequence":"additional","affiliation":[{"name":"The Xinqiao Hospital of Army Medical University","place":["Chongqing, People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1904-791X","authenticated-orcid":false,"given":"Yimei","family":"Feng","sequence":"additional","affiliation":[{"name":"The Xinqiao Hospital of Army Medical University","place":["Chongqing, People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Xinqiao Hospital of Army Medical University","place":["Chongqing, People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"e_1_3_3_2_1","article-title":"How we treat primary immune thrombocytopenia in adults","volume":"16","author":"Liu XG","year":"2023","unstructured":"Liu XG, Hou Y, Hou M. How we treat primary immune thrombocytopenia in adults. J Hematol OncolJ Hematol Oncol. 2023;16.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"e_1_3_3_3_1","first-page":"115","article-title":"Response and remission after first-line corticosteroid therapy in primary immune thrombocytopenia","author":"Mapimhidze D","year":"2025","unstructured":"Mapimhidze D, Bailly J, Brown K, et al. Response and remission after first-line corticosteroid therapy in primary immune thrombocytopenia. Samj South African Med Jl. 2025: 115.","journal-title":"Samj South African Med Jl"},{"key":"e_1_3_3_4_1","article-title":"Management of Adult Patients with Newly Diagnosed or Relapsed Primary Immune Thrombocytopenia in Eastern Austria","author":"Rast J","year":"2024","unstructured":"Rast J, Schramm T, Mehic D, et al. Management of Adult Patients with Newly Diagnosed or Relapsed Primary Immune Thrombocytopenia in Eastern Austria. Hamostaseologie. 2024.","journal-title":"Hamostaseologie"},{"key":"e_1_3_3_5_1","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00277-023-05114-8","article-title":"Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus","volume":"102","author":"Pulanic D","year":"2023","unstructured":"Pulanic D, Batorova A, Bodo I, et al. Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus. Ann Hematol. 2023;102:715\u2013727.","journal-title":"Ann Hematol"},{"key":"e_1_3_3_6_1","first-page":"81","article-title":"Thrombopoietin receptor agonists for refractory thrombocytopenia in patients after autologous hematopoietic stem cell transplantation","author":"Wang D","year":"2023","unstructured":"Wang D, Lang T, Zeng HQ, et al. Thrombopoietin receptor agonists for refractory thrombocytopenia in patients after autologous hematopoietic stem cell transplantation. Transpl Immunol. 2023: 81.","journal-title":"Transpl Immunol"},{"key":"e_1_3_3_7_1","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1186\/s40001-025-02850-7","article-title":"Real-world experience of hetrombopag in immune thrombocytopenia treatment: a retrospective cohort study","volume":"30","author":"Wang D","year":"2025","unstructured":"Wang D, Chang C, Zou Z, et al. Real-world experience of hetrombopag in immune thrombocytopenia treatment: a retrospective cohort study. Eur J Med Res. 2025;30:574.","journal-title":"Eur J Med Res"},{"key":"e_1_3_3_8_1","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1080\/16078454.2022.2151230","article-title":"Progress on the efficacy and potential mechanisms of rapamycin in the treatment of immune thrombocytopenia","volume":"27","author":"Wang D","year":"2022","unstructured":"Wang D, Cassady K, Zou Z, et al. Progress on the efficacy and potential mechanisms of rapamycin in the treatment of immune thrombocytopenia. Hematology. 2022;27:1282\u20131289.","journal-title":"Hematology"},{"key":"e_1_3_3_9_1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.5694\/mja2.51284","article-title":"Consensus guidelines for the management of adult immune thrombocytopenia in Australia and New Zealand","volume":"216","author":"Choi PY","year":"2022","unstructured":"Choi PY, Merriman E, Bennett A, et al. Consensus guidelines for the management of adult immune thrombocytopenia in Australia and New Zealand. Med J Aust. 2022;216:43\u201352.","journal-title":"Med J Aust"},{"key":"e_1_3_3_10_1","doi-asserted-by":"crossref","first-page":"953716","DOI":"10.3389\/fimmu.2022.953716","article-title":"Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently?","volume":"13","author":"Lv Y","year":"2022","unstructured":"Lv Y, Shi H, Liu H, et al. Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently? Front Immunol. 2022;13:953716.","journal-title":"Front Immunol"},{"key":"e_1_3_3_11_1","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3389\/fmed.2020.00110","article-title":"Sirolimus as Rescue Therapy for Refractory\/Relapsed Immune Thrombocytopenia: Results of a Single-Center, Prospective, Single-Arm Study","volume":"7","author":"Feng Y","year":"2020","unstructured":"Feng Y, Xiao Y, Yan H, et al. Sirolimus as Rescue Therapy for Refractory\/Relapsed Immune Thrombocytopenia: Results of a Single-Center, Prospective, Single-Arm Study. Front Med (Lausanne). 2020;7:110.","journal-title":"Front Med (Lausanne)"},{"key":"e_1_3_3_12_1","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s12185-018-2445-z","article-title":"Chinese guidelines for treatment of adult primary immune thrombocytopenia","volume":"107","author":"Liu XG","year":"2018","unstructured":"Liu XG, Bai XC, Chen FP, et al. Chinese guidelines for treatment of adult primary immune thrombocytopenia. Int J Hematol. 2018;107:615\u2013623.","journal-title":"Int J Hematol"},{"key":"e_1_3_3_13_1","doi-asserted-by":"crossref","first-page":"2119043","DOI":"10.1080\/21645515.2022.2119043","article-title":"Clinical characteristics in immune thrombocytopenia patients after COVID-19 vaccination","volume":"18","author":"Feng Y","year":"2022","unstructured":"Feng Y, Quan Y, Cassady K, et al. Clinical characteristics in immune thrombocytopenia patients after COVID-19 vaccination. Hum Vaccin Immunother. 2022;18:2119043.","journal-title":"Hum Vaccin Immunother"},{"key":"e_1_3_3_14_1","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/bjh.18893","article-title":"Combining thrombopoietin receptor agonists with immunosuppressive drugs in adult patients with multirefractory immune thrombocytopenia, an update on the French experience","volume":"202","author":"Crickx E","year":"2023","unstructured":"Crickx E, Ebbo M, Riviere E, et al. Combining thrombopoietin receptor agonists with immunosuppressive drugs in adult patients with multirefractory immune thrombocytopenia, an update on the French experience. Br J Haematol. 2023;202:883\u2013889.","journal-title":"Br J Haematol"},{"key":"e_1_3_3_15_1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13045-021-01047-9","article-title":"A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia","volume":"14","author":"Mei H","year":"2021","unstructured":"Mei H, Liu X, Li Y, et al. A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. J Hematol Oncol. 2021;14:37.","journal-title":"J Hematol Oncol"},{"key":"e_1_3_3_16_1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/bjh.14380","article-title":"Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia","volume":"176","author":"Yang R","year":"2017","unstructured":"Yang R, Li J, Jin J, et al. Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia. Br J Haematol. 2017;176:101\u2013110.","journal-title":"Br J Haematol"},{"key":"e_1_3_3_17_1","doi-asserted-by":"crossref","first-page":"103297","DOI":"10.1016\/j.autrev.2023.103297","article-title":"Development of systemic lupus erythematosus in patients with immune thrombocytopenic purpura: A systematic meta-analysis","volume":"22","author":"Pamuk ON","year":"2023","unstructured":"Pamuk ON, Ali SM, Hasni S. Development of systemic lupus erythematosus in patients with immune thrombocytopenic purpura: A systematic meta-analysis. Autoimmun Rev. 2023;22:103297.","journal-title":"Autoimmun Rev"},{"key":"e_1_3_3_18_1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bjh.18795","article-title":"Antinuclear antibodies in childhood immune thrombocytopaenia: An increased risk for development of autoimmune disorders?","volume":"202","author":"Kapur R.","year":"2023","unstructured":"Kapur R. Antinuclear antibodies in childhood immune thrombocytopaenia: An increased risk for development of autoimmune disorders? Br J Haematol. 2023;202:215\u2013216.","journal-title":"Br J Haematol"},{"key":"e_1_3_3_19_1","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bjh.18732","article-title":"The effect of antinuclear antibody titre and its variation on outcomes in children with primary immune thrombocytopenia","volume":"202","author":"Liu J","year":"2023","unstructured":"Liu J, Zhang Y, Li Z, et al. The effect of antinuclear antibody titre and its variation on outcomes in children with primary immune thrombocytopenia. Br J Haematol. 2023;202:412\u2013421.","journal-title":"Br J Haematol"},{"key":"e_1_3_3_20_1","doi-asserted-by":"crossref","first-page":"2551454","DOI":"10.1080\/16078454.2025.2551454","article-title":"Antinuclear antibody positive in patients with primary immune thrombocytopenia: incidence and risk prediction of developing autoimmune diseases","volume":"30","author":"Liang H","year":"2025","unstructured":"Liang H, Dong S, Sun C, et al. Antinuclear antibody positive in patients with primary immune thrombocytopenia: incidence and risk prediction of developing autoimmune diseases. Hematology. 2025;30:2551454.","journal-title":"Hematology"},{"key":"e_1_3_3_21_1","doi-asserted-by":"crossref","first-page":"611690","DOI":"10.3389\/fonc.2020.611690","article-title":"The Role of mTOR Inhibitors in Hematologic Disease: From Bench to Bedside","volume":"10","author":"Feng Y","year":"2020","unstructured":"Feng Y, Chen X, Cassady K, et al. The Role of mTOR Inhibitors in Hematologic Disease: From Bench to Bedside. Front Oncol. 2020;10:611690.","journal-title":"Front Oncol"},{"key":"e_1_3_3_22_1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/MBC.0000000000001303","article-title":"Clinical study reveals the efficacy of sirolimus in treating primary immune thrombocytopenia: findings from a single-center study","volume":"35","author":"Feng Y","year":"2024","unstructured":"Feng Y, Meng H, Mu C, et al. Clinical study reveals the efficacy of sirolimus in treating primary immune thrombocytopenia: findings from a single-center study. Blood Coagul Fibrinolysis. 2024;35:155\u2013160.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"e_1_3_3_23_1","doi-asserted-by":"crossref","first-page":"109475","DOI":"10.1016\/j.thromres.2025.109475","article-title":"Inhibiting mTORC1 pathway by rapamycin restores the balance of CD8(+) T cell subsets and reduces CD8(+) T cell-mediated platelet destruction in immune thrombocytopenia","volume":"254","author":"Ni X","year":"2025","unstructured":"Ni X, Guo J, Zhu X, et al. Inhibiting mTORC1 pathway by rapamycin restores the balance of CD8(+) T cell subsets and reduces CD8(+) T cell-mediated platelet destruction in immune thrombocytopenia. Thromb Res. 2025;254:109475.","journal-title":"Thromb Res"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.13201\/j.issn.11004\u201312806.12025.13205.13001"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn141217\u201320250228\u201320200052"},{"key":"e_1_3_3_26_1","first-page":"1","article-title":"HLA haploidentical HSCT: from immune imbalance to a platform for immune homeostasis restoration","volume":"1","author":"Guo H","year":"2025","unstructured":"Guo H, Xu Z, Pei X, et al. HLA haploidentical HSCT: from immune imbalance to a platform for immune homeostasis restoration. Immun Inflam. 2025;1:1\u201313.","journal-title":"Immun Inflam"},{"key":"e_1_3_3_27_1","doi-asserted-by":"crossref","first-page":"217264","DOI":"10.1016\/j.canlet.2024.217264","article-title":"Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update","volume":"605","author":"Wang Y","year":"2024","unstructured":"Wang Y, Chang YJ, Chen J, et al. Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update. Cancer Lett. 2024;605:217264.","journal-title":"Cancer Lett"},{"key":"e_1_3_3_28_1","doi-asserted-by":"crossref","first-page":"2277831","DOI":"10.1080\/09537104.2023.2277831","article-title":"Optimizing the therapeutic window of sirolimus by monitoring blood concentration for the treatment of immune thrombocytopenia","volume":"34","author":"Zhang Y","year":"2023","unstructured":"Zhang Y, Quan Y, Wang D, et al. Optimizing the therapeutic window of sirolimus by monitoring blood concentration for the treatment of immune thrombocytopenia. Platelets. 2023;34:2277831.","journal-title":"Platelets"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/16078454.2026.2642515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T03:50:48Z","timestamp":1773805848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/16078454.2026.2642515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/16078454.2026.2642515"],"URL":"https:\/\/doi.org\/10.1080\/16078454.2026.2642515","relation":{},"ISSN":["1607-8454"],"issn-type":[{"value":"1607-8454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=yhem20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=yhem20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-01-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2642515"}}